 Connection
Daniel LaBarbera to Enzyme Inhibitors
This is a "connection" page, showing publications Daniel LaBarbera has written about Enzyme Inhibitors.
|
|
| |
Connection Strength |
|
 |
|
 |
| |
1.151 |
|
|
|
-
Abbott JM, Zhou Q, Esquer H, Pike L, Broneske TP, Rinaldetti S, Abraham AD, Ramirez DA, Lunghofer PJ, Pitts TM, Regan DP, Tan AC, Gustafson DL, Messersmith WA, LaBarbera DV. First-in-Class Inhibitors of Oncogenic CHD1L with Preclinical Activity against Colorectal Cancer. Mol Cancer Ther. 2020 08; 19(8):1598-1612.
Score: 0.558
-
Li L, Chang KC, Zhou Y, Shieh B, Ponder J, Abraham AD, Ali H, Snow A, Petrash JM, LaBarbera DV. Design of an amide N-glycoside derivative of ?-glucogallin: a stable, potent, and specific inhibitor of aldose reductase. J Med Chem. 2014 Jan 09; 57(1):71-7.
Score: 0.357
-
Kalita D, Holm DG, LaBarbera DV, Petrash JM, Jayanty SS. Inhibition of a-glucosidase, a-amylase, and aldose reductase by potato polyphenolic compounds. PLoS One. 2018; 13(1):e0191025.
Score: 0.118
-
Chang KC, Snow A, LaBarbera DV, Petrash JM. Aldose reductase inhibition alleviates hyperglycemic effects on human retinal pigment epithelial cells. Chem Biol Interact. 2015 Jun 05; 234:254-60.
Score: 0.094
-
Chang KC, Ponder J, Labarbera DV, Petrash JM. Aldose reductase inhibition prevents endotoxin-induced inflammatory responses in retinal microglia. Invest Ophthalmol Vis Sci. 2014 May 02; 55(5):2853-61.
Score: 0.023
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|